Protease inhibitor and NRTIs safe, effective in HIV treatment

July 19, 2014
Protease inhibitor + NRTIs safe, effective in HIV treatment

(HealthDay)—An HIV treatment regimen of a boosted protease inhibitor (lopinavir) combined with nucleoside reverse-transcriptase inhibitors (NRTIs) is safe and effective in low-resource settings, according to a study published in the July 17 issue of the New England Journal of Medicine.

Nicholas I. Paton, M.D., from University College London, and colleagues conducted an open-label trial in sub-Saharan Africa involving 1,277 HIV-infected adults and adolescents with first-line treatment failure. Participants were randomized to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group; 426 patients); a protease inhibitor plus raltegravir (raltegravir group; 433 patients); or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir (monotherapy group; 418 patients).

The researchers found that good disease control was achieved in 60 percent of the NRTI group, 64 percent of the raltegravir group (P = 0.21 versus the NRTI group; superiority of raltegravir not shown), and 55 percent of the monotherapy group (noninferiority of monotherapy not shown). Rates of adverse events (grade 3 or 4) were similar among the groups (P = 0.82). In the NRTI group, viral load <400 copies per milliliter was achieved in 86 percent of patients, compared with 86 percent in the raltegravir group (P = 0.97) and 61 percent in the monotherapy group (P < 0.001).

"When given with a in second-line therapy, NRTIs retained substantial virologic activity without evidence of increased toxicity, and there was no advantage to replacing them with raltegravir," the authors write.

Trial medication was donated by pharmaceutical companies.

Explore further: HIV therapy just got easier: Fewer drugs may be needed for treatment-experienced patients

More information: Abstract
Full Text

Related Stories

HIV therapy just got easier: Fewer drugs may be needed for treatment-experienced patients

March 7, 2013
A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression – the primary goal of HIV therapy – without incorporating the traditional class of HIV medications into their treatment ...

Protease inhibitor resistance involves multiple stages of the HIV-1 life cycle

August 27, 2013
HIV-1 protease inhibitors are very effective antiviral drugs. These drugs target HIV-1 proteases, which are required for viral replication. Despite the success of protease inhibitors for suppressing HIV-1, some patients do ...

HIV treatment reduces risk of malaria recurrence in children, study shows

November 28, 2012
A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health.

Dolutegravir in HIV-1 infection: Added benefit in adult patients

May 21, 2014
Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit ...

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.